Fabrice Pierre

USPTO Granted Patents = 20 (Patent Applications = 16)

CIPO Patents = 4

EPO Patents = 8 (Patent Applications = 12)

Average Co-Inventor Count = 5.7

ph-index = 8

Forward Citations = 118(Granted Patents)

Company Filing History:

8 out of 21

Cylene Pharmaceuticals, Inc.

patents

7 out of 1,151

Vertex Pharmaceuticals, Inc.

patents

4 out of 11

Senhwa Biosciences, Inc.

Years Active: 2008-2025

Loading Chart...

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12319693 - Crystalline forms of CFTR modulators (2025-06-03),

2. 12122788 - Process of making CFTR modulators (2024-10-22),

3. 11873300 - Crystalline forms of CFTR modulators (2024-01-16),

4. 11866450 - Modulators of Cystic Fibrosis Transmembrane Conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators (2024-01-09),

5. 11591350 - Modulators of cystic fibrosis transmembrane conductance regulator (2023-02-28),

6. 11584761 - Process of making CFTR modulators (2023-02-21),

7. 11066417 - Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators (2021-07-20),

8. 9303033 - Pyrazolopyrimidines and related heterocycles as CK2 inhibitors (2016-04-05),

9. 9062043 - Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators (2015-06-23),

10. 8853234 - Quinolone analogs and methods related thereto (2014-10-07),

11. 8575177 - Pyrazolopyrimidines and related heterocycles as CK2 inhibitors (2013-11-05),

12. 8168651 - Protein kinase modulators (2012-05-01),

13. 7928100 - Quinolone analogs and methods related thereto (2011-04-19),

14. 7910600 - Therapeutic kinase modulators (2011-03-22),

15. 7834180 - Methods of preparing quinolone analogs (2010-11-16),

Title: Innovations of Fabrice Pierre: Trailblazer in CFTR Modulators

Introduction: Fabrice Pierre, based in La Jolla, California, is a distinguished inventor with a remarkable portfolio consisting of 19 patents. His work has significantly contributed to the field of pharmaceuticals, particularly in the development of treatments for cystic fibrosis.

Latest Patents: Pierre's latest innovations include a revolutionary process of making CFTR modulators. This disclosure provides detailed processes for synthesizing Compound I and its pharmaceutically acceptable salts. Additionally, he has developed crystalline forms of CFTR modulators, including not just Compound I but also its salts, solvates, and hydrates. These patents detail pharmaceutical compositions incorporating these compounds, methods of treating cystic fibrosis, and techniques for producing these innovative solutions.

Career Highlights: Throughout his career, Fabrice Pierre has been associated with prominent companies such as Cylene Pharmaceuticals and Vertex Pharmaceuticals. His work at these institutions has further advanced his research and development endeavors, landing him a pivotal role in pharmaceutical innovation.

Collaborations: Collaboration has been a key aspect of Pierre's career. Notably, he has worked closely with esteemed colleagues like Michael Schwaebe and Jeffrey Paul Whitten. Their combined expertise has undoubtedly enriched the research environment, contributing to significant advancements in their respective fields.

Conclusion: Fabrice Pierre stands out as a vital contributor to the pharmaceutical industry, particularly in the realm of cystic fibrosis treatment. His dedication to innovation and teamwork showcases the impact that collaboration and research can have on developing life-changing therapies.

This text is generated by artificial intelligence and may not be accurate.